NF‐κB pathway as a molecular target for curcumin in diabetes mellitus treatment: Focusing on oxidative stress and inflammation

Author:

Zamanian Mohammad Yasin12ORCID,Alsaab Hashem O.3,Golmohammadi Maryam4,Yumashev Alexey5,Jabba Abeer Mhussan6,Abid Mohammed Kadhem7,Joshi Abhishek8,Alawadi Ahmed Hussien91011,Jafer Noor S.12,Kianifar Farzaneh13,Obakiro Samuel Baker14ORCID

Affiliation:

1. Department of Physiology Hamadan University of Medical Sciences Hamadan Iran

2. Department of Pharmacology and Toxicology, School of Pharmacy Hamadan University of Medical Sciences Hamadan Iran

3. Department of Pharmaceutics and Pharmaceutical Technology Taif University Taif Saudi Arabia

4. School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran

5. Department of Prosthetic Dentistry Sechenov First Moscow State Medical University Moscow Russia

6. Colleges of Pharmacy National University of Science and Technology Dhi Qar Iraq

7. Department of Anesthesia, College of Health & Medical Technology Al‐Ayen University Nasiriyah Iraq

8. Department of Liberal Arts School of Liberal Arts Uttaranchal University Dehradun India

9. College of Technical Engineering The Islamic University Najaf Iraq

10. College of Technical Engineering The Islamic University of Al Diwaniyah Al Diwaniyah Iraq

11. College of Technical Engineering The Islamic University of Babylon Babylon Iraq

12. Department of Medical Laboratory Technologies Al Rafidain University College Bagdad Iraq

13. School of Medicine Iran University of Medical Sciences Tehran Iran

14. Department of Pharmacology and Therapeutics, Faculty of Health Sciences Busitema University Mbale Uganda

Abstract

AbstractDiabetes mellitus (DM) is a collection of metabolic disorder that is characterized by chronic hyperglycemia. Recent studies have demonstrated the crucial involvement of oxidative stress (OS) and inflammatory reactions in the development of DM. Curcumin (CUR), a natural compound derived from turmeric, exerts beneficial effects on diabetes mellitus through its interaction with the nuclear factor kappa B (NF‐κB) pathway. Research indicates that CUR targets inflammatory mediators in diabetes, including tumor necrosis factor α (TNF‐α) and interleukin‐6 (IL‐6), by modulating the NF‐κB signaling pathway. By reducing the expression of these inflammatory factors, CUR demonstrates protective effects in DM by improving pancreatic β‐cells function, normalizing inflammatory cytokines, reducing OS and enhancing insulin sensitivity. The findings reveal that CUR administration effectively lowered blood glucose elevation, reinstated diminished serum insulin levels, and enhanced body weight in Streptozotocin ‐induced diabetic rats. CUR exerts its beneficial effects in management of diabetic complications through regulation of signaling pathways, such as calcium–calmodulin (CaM)‐dependent protein kinase II (CaMKII), peroxisome proliferator‐activated receptor gamma (PPAR‐γ), NF‐κB, and transforming growth factor β1 (TGFB1). Moreover, CUR reversed the heightened expression of inflammatory cytokines (TNF‐α, Interleukin‐1 beta (IL‐1β), IL‐6) and chemokines like MCP‐1 in diabetic specimens, vindicating its anti‐inflammatory potency in counteracting hyperglycemia‐induced alterations. CUR diminishes OS, avert structural kidney damage linked to diabetic nephropathy, and suppress NF‐κB activity. Furthermore, CUR exhibited a protective effect against diabetic cardiomyopathy, lung injury, and diabetic gastroparesis. Conclusively, the study posits that CUR could potentially offer therapeutic benefits in relieving diabetic complications through its influence on the NF‐κB pathway.

Publisher

Wiley

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3